<DOC>
	<DOCNO>NCT01954992</DOCNO>
	<brief_summary>The study design ass whether glufosfamide provide additional survival benefit compare bolus 5-FU patient metastatic pancreatic cancer already progress failed therapy gemcitabine base first line regimen .</brief_summary>
	<brief_title>Glufosfamide Versus 5-FU Second Line Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>At least 18 year age Pancreatic adenocarcinoma proven either histology ( surgical biopsy ) cytology ( CT endoscopicguided ) Metastatic pancreatic cancer Disease progression treatment gemcitabine ( alone combination agent ; regular , radiosensitizing , dos ) Measurable nonmeasurable disease RECIST criterion ( least one target nontarget lesion ) Recovered reversible toxicity prior therapy ECOG performance status 01 All woman childbearing potential men must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) entry study 6 month last dose chemotherapy Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee More one prior systemic therapy regimen metastatic pancreatic cancer ( radiosensitizing dose 5FU gemcitabine time initial radiotherapy count prior systemic therapy regimen ) Hormonal therapy , radiation therapy , biologic therapy , chemotherapy systemic antitumor therapy pancreatic cancer within 14 day prior Cycle 1 Day 1 Insulindependent diabetes mellitus ( patient type 2 diabetes control oral glucose lower agent occasional use insulin permit study ) Symptomatic brain metastasis ( baseline CT scan require asymptomatic patient ) Active clinically significant infection require antibiotic Known HIV positive active hepatitis B C Recent ( one year ) history symptom cardiovascular disease ( NYHA Class 2 , 3 , 4 ) , particularly coronary artery disease , arrhythmias conduction defect risk cardiovascular instability , uncontrolled hypertension , clinically significant pericardial effusion , congestive heart failure No active malignancy ( treat nonmelanoma skin cancer treat situ cancer ) within past year Major surgery within 3 week start study treatment , without complete recovery Clinically significant abnormality laboratory test result ( include complete blood count , chemistry panel include electrolyte , urinalysis ) Hemoglobin &lt; 9 g/dL ( may receive transfusion erythropoietin maintain ) ANC &lt; 1500/μL Platelet count &lt; 100,000/μL Total bilirubin &gt; 1.5×ULN AST/ALT &gt; 2.5fold ULN ( &gt; 5fold ULN liver metastasis ) Phosphorus &lt; LLN Potassium &lt; LLN Serum creatinine &gt; 2 mg/dL Creatinine clearance &lt; 60 mL/min ( calculate CockcroftGault formula ) Females pregnant breastfeed Participation investigational drug device study within 14 day first day dose study Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk patient study Any medical history , concurrent disease concomitant medication could reasonably predispose patient renal insufficiency study treatment Contraindication unwillingness undergo multiple CT scan Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>glufosfamide</keyword>
	<keyword>5-FU</keyword>
	<keyword>metastatic pancreatic adenocarcinoma</keyword>
</DOC>